Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company developing novel serotonergic agonists (NSAs) for mental health conditions, announced that CEO Michael Halstead will participate in a fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference. The conference is scheduled for September 14-16, 2026, in New York City.
The fireside chat is set to be webcast live on September 14 at 9 a.m. EDT, with a replay available on the Events & Presentations page of Helus Pharma’s investor relations website. This presentation provides investors and industry stakeholders an opportunity to gain insights into the company’s strategic direction, clinical developments, and potential market impact.
Helus Pharma, the commercial operating name of Cybin Inc., founded in 2019, is dedicated to helping minds heal by developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. These investigational therapies aim to address the substantial unmet need for individuals suffering from depression, anxiety, and other mental health conditions.
The company’s lead product candidate, HLP003, is a proprietary NSA currently in Phase 3 clinical development for the adjunctive treatment of major depressive disorder (MDD). It has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA), underscoring its potential to offer significant improvement over existing therapies. Additionally, HLP004, another proprietary NSA, is in Phase 2 development for generalized anxiety disorder (GAD). Helus Pharma also maintains an extensive research portfolio of other investigational NSAs.
The announcement comes at a time when mental health disorders are a growing global concern. According to the World Health Organization, depression is a leading cause of disability worldwide, and anxiety disorders are among the most common mental health conditions. Current treatments often have limitations, including delayed onset of action, inadequate response rates, and side effects. Helus Pharma’s focus on NSAs aims to provide rapid and durable improvements in mental health by targeting neuroplasticity, the brain’s ability to reorganize and form new neural connections.
The company operates in Canada, the United States, the United Kingdom, and Ireland, positioning it to conduct global clinical trials and potentially commercialize its therapies across multiple regions. The participation of CEO Michael Halstead at such a prestigious conference highlights the company’s commitment to engaging with the investment community and sharing progress on its clinical programs.
Investors and industry observers will be keen to hear about the latest developments in Helus Pharma’s pipeline, including enrollment updates for the Phase 3 trial of HLP003 and any insights into the Phase 2 study for HLP004. The fireside chat could also provide clarity on the company’s regulatory strategy, manufacturing capabilities, and commercialization plans if approvals are granted.
The H.C. Wainwright conference is known for bringing together leading companies in the biotech and pharmaceutical sectors with institutional investors, analysts, and other key stakeholders. For Helus Pharma, this platform offers a significant opportunity to raise its profile and attract potential partnerships or investment.
As the company advances its clinical programs, the broader implications for mental health treatment are substantial. If HLP003 or HLP004 demonstrate success in clinical trials, they could offer new options for patients who have not responded to conventional antidepressants or anxiolytics. The potential to enhance neuroplasticity represents a novel mechanism of action that might differentiate Helus Pharma’s candidates in a crowded market.
For more information about Helus Pharma and its developments, visit Helus Pharma's website or access the full press release here. The webcast and replay will be accessible via the company's investor relations page, providing transparency for all interested parties.
